アデニンは,本質的に乱れたα-シヌクレインタンパク質のA53T変異体の単体構造を強化する
Payal Singh1, Almas Akhtar1, Nikita Admane1
1School of Biotechnology, Jawaharlal Nehru University, New Delhi 110067, India.
Computational biology and chemistry
|August 29, 2025
まとめ
アデニンは,早期発症のパーキンソン病 (PD) の重要な要因であるA53Tアルファシヌクレインのアミロイド結合を選択的に防ぐ. この核塩基はタンパク質の単体形態を安定させ PDの潜在的な治療戦略を提供します.
科学分野:
- 生物化学
- 神経科学
- 構造生物学
背景:
- パーキンソン病 (PD) は,アルファ-シヌクレイン (α-Syn) アミロイド集合体,特にルイ体の特徴です.
- α- SynのA53T変異は,早期発症のPDと関連しており,急速な集積とプロトフィブリル形成が特徴です.
研究 の 目的:
- A53T α-Synのアミロイド変換に対するアデニンの影響を調査する.
- アデニンがA53Tα-Synの結合を阻害できるかどうかを判断する.
主な方法:
- 生物物理技術 (チオフラビンT結合,TEM,AFM,DLS) と計算方法 (REMDシミュレーション)
- アデニンのA53Tα-Syn単体との相互作用とそのアミロイド形成への影響の分析.
主要な成果:
- アデニンは,NACドメインとの非共性相互作用によって単体A53Tα-Synを安定させる.
- アデニンは,野生型α-Synに影響を与えることなく,A53Tα-Synアミロジネシスを特に抑制する.
- REMDシミュレーションと生理学的データは,アデニンの存在でβシート含有量とアミロイド形成の減少を確認しています.
結論:
- アデニンは,A53T α-シンアミロイドの形成を選択的に防止し,その単体状態を安定させます.
- アデニンは,早期発症のパーキンソン病の治療の可能性を示しています.
- アデニンの治療効果を調査するために,細胞および動物モデルでのさらなる研究が必要である.
さらに関連する動画
08:40Millisecond Hydrogen/Deuterium-Exchange Mass Spectrometry for the Study of Alpha-Synuclein Structural Dynamics Under Physiological Conditions
Published on: June 23, 2022
3.0K
08:24A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
Published on: November 25, 2022
2.3K
関連する概念動画
Protein Folding
8.6K
Proteins are chains of amino acids linked together by peptide bonds. Upon synthesis, a protein folds into a three-dimensional conformation, critical to its biological function. Interactions between its constituent amino acids guide protein folding, and hence the protein structure is primarily dependent on its amino acid sequence.
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
8.6K
Amyloid Fibrils
9.8K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.8K
Conserved Binding Sites
4.3K
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
4.3K
Molecular Chaperones and Protein Folding
18.4K
The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
The...
18.4K
Protein Organization
143.0K
Overview
143.0K
Allosteric Proteins-ATCase
5.9K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.9K
